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ceftriaxone and convenience of outpatient paren-
teral therapy, this antibiotic was continued to
complete a 10-day course. On extensive questioning,
the patient denied contact with any cat, dog, or
other animal.  He had recently traveled to Nigeria
but denied even transient animal contact.
Since 1966, three cases of P. multocida epi-
glottitis have been reported (2-4). Although no
direct culture of the epiglottis was performed in
the present case, the clinical syndrome and the
absence of any other focus accounting for P.
multocida bacteremia strongly suggest that this
organism caused the epiglottitis. Including the
present case, three of the four reported cases
have occurred since 1993, which suggests that
either earlier cases were not recognized or the
incidence of this condition may be increasing. In
all three previous cases of P. multocida epiglot-
titis, the patients had cats as pets. As in the
current case, the clinical features of P. multo-
cida epiglottitis were indistinguishable from
epiglottitis secondary to more common bacterial
pathogens. However, the cases were all asso-
ciated with positive blood cultures. In contrast, a
23% rate of bacteremia was reported in a series of
epiglottitis cases in adults (including patients
with blood cultures positive for Haemophilus
influenzae type b or Group A streptococci)(5).
The vehicle of infection for this patient
remains unknown, as human-to-human trans-
mission has not been documented. This case
demonstrates that epiglottitis due to P. multo-
cida, a rare condition that may be increasing in
frequency, need not be accompanied by recognized
exposure to animals.
Michael Glickman and Robert S. Klein
Montefiore Medical Center and the Albert Einstein
College of Medicine, New York, New York, USA
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Hemolytic Uremic Syndrome
Surveillance to Monitor Trends in
Infection with Escherichia coli O157:H7
and Other Shiga Toxin-Producing
E. coli
To the Editor: In the past 15 years, knowledge
about the role of Shiga toxin-producing Esche-
richia coli (STEC) in human disease has expanded
rapidly. The most distinctive complication of
STEC infection is diarrhea-associated hemolytic
uremic syndrome (HUS), a major cause of acute
renal failure in U.S. children. Other manifes-
tations of STEC infection can range from mild
diarrhea to severe hemorrhagic colitis, thrombotic
thrombocytopenic purpura, and death (1). In the
United States, O157 is the most common STEC
and causes an estimated 20,000 infections and
250 deaths annually. E. Coli O157 outbreaks
associated with beef have caused concern among
public health workers, clinicians, and the public,
prompting major changes in clinical and labora-
tory practice, meat production, and food pre-
paration. However, critical questions remain
unanswered. Have prevention measures decreased
risk? Are new sources of STEC infections
emerging? Is the incidence of O157 infection
changing? How much illness is due to STEC of
serotypes other than O157?
Diarrhea-associated HUS is associated with
Shiga toxin, which is produced in quantity only
by STEC and by Shigella dysenteriae type 1;
approximately 90% of HUS cases are diarrhea-
associated (2,3). In the United States, where S.
dysenteriae type 1 infections are very rare, STEC
infections are the cause of virtually all diarrhea-
associated HUS. The incidence of HUS in North
America is about three cases per 100,000 chil-
dren under 5 years of age per year; the rate
among older children is somewhat lower, and the
rate among adults is not known (2-6). HUS
complicates approximately 5% to 10% of O157
infections and an unknown percentage of non-
O157 STEC infections (1). Except for supportive
care and hemodialysis, no treatment has been
shown to decrease the severity of illness or to pre-
vent complications. The sequelae of HUS—death
in 3% to 5% of cases (2,3,5) and long-term renal dys-
function in 10% to 30% of survivors (6)—and the
lack of specific therapy make prevention critical.410 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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Important changes that may decrease the
incidence of STEC infection and HUS in the
United States are occurring now. For example,
because most outbreaks of STEC infections and
HUS have been linked to the consumption of
undercooked beef, raw milk, or other products
contaminated by the intestinal contents of cattle
(1), some U.S. meat producers have changed
processing practices to decrease bacterial con-
tamination of meat. As a result of an O157
outbreak caused by consumption of frozen pre-
cooked meat patties, federal regulations requiring
that this product be cooked adequately to kill
O157 were implemented. New requirements that
raw meat be labeled with instructions for safe
handling and that carcasses be tested for O157
have also recently been implemented nationwide.
New vehicles of O157 transmission, for example,
dry-cured salami, fermented sausage, and unpas-
teurized apple juice, have been discovered,
prompting the reconsideration of manufacturing
processes for these products. Because O157 can
be transmitted from person to person (7,8), public
health recommendations for control measures to
prevent transmission from infected persons have
been developed and disseminated (1,8). All these
prevention measures show promise; however,
their effectiveness has not been documented.
Other changes may not be so salutary. For
instance, an increase in international trade in beef
and other foods may increase exposure to non-
O157 STEC in the United States. Argentina,
which has a particularly high incidence of HUS (9),
has recently gained approval to start exporting
beef to the United States. In Australia, which
also exports beef to the United States, a large out-
break of infections with Shiga toxin-producing
E. coli O111:NM in 1995 was linked to a sausage
product; in this outbreak, 23 children became ill
with HUS, and one died (10).
Current surveillance methods are unlikely to
detect the impact of any of these changes because
of two fundamental problems. The first is that
changing rates of reported O157 infections and
outbreaks do not necessarily reflect actual changes
in O157 incidence; it is impossible to tell how
much of the marked increase in these reports
may be due to greater awareness of rather than
actual increase in the incidence of infection. As
the public health importance of O157 has become
clear, many states have attempted to improve
surveillance by mandating reporting of O157
infections. Between 1987 and February 1997, the
number of states requiring such reporting
increased from 3 to 42 (CDC, unpub. data). In
both 1994 and 1995, 32 outbreaks were reported
to CDC, the largest numbers ever, bringing the
total number of reported U.S. outbreaks to 102;
these comprised 2,806 illnesses and 23 deaths
(CDC, unpub. data). Both heightened clinician
awareness and changes in laboratory stool
screening practices (11) have dramatically improved
recognition of O157 infections, which has clear
public health benefits. For example, if clinical
laboratories in Nevada had been screening stool
specimens routinely for O157 in 1993, one of the
largest clusters of O157 infections ever
investigated in the United States might have
been recognized and controlled more quickly (12).
On the other hand, changing rates of ascer-
tainment of these infections means that O157-
based surveillance systems have not been able to
show trends in incidence and may not be able to
do so reliably in the future.
The second fundamental problem is that sur-
veillance for O157 infections cannot detect trends
in non-O157 STEC infections. Non-O157 STEC
are not likely to be detected by plating stool
specimens on sorbitol-MacConkey agar (13), the
method most commonly used to screen for O157.
This screening test is based on the fact that,
unlike most E. coli, very few O157 strains fer-
ment sorbitol rapidly; since most other STEC do
ferment sorbitol, this test does not detect them.
Yet the non-O157 STEC pose a threat to public
health in the United States. Non-O157 STEC,
including  E. coli O111:NM and E. coli O104:H21,
have caused recent outbreaks detected only
because of unusual circumstances. Similarly,
sorbitol-positive O157, which recently caused a
large outbreak in Germany (pers. comm. Dr.
Andrea Ammon, Robert Koch Institute, Germany),
would not be detected by current screening prac-
tices. In other countries, such as Australia (10)
and Argentina (9), non-O157 STEC infections
appear to be more common than O157 infections,
and in Germany, non-O157 STEC have replaced
O157 as the STEC most commonly isolated in
HUS cases since 1989 (14). As travel and inter-
national trade in food increase, Americans’ risk of
exposure to these other STEC also increases. How-
ever, even major non-O157 STEC outbreaks might
not be detected by current U.S. surveillance.
To address these two fundamental problems
with current surveillance, the Centers for Disease
Control and Prevention has recently initiated411 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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active HUS surveillance in sentinel sites, which
include Connecticut, Georgia, Minnesota, Oregon,
and Alameda County, California and which may
be expanded in the future. HUS cases, identified
by a definition designed for surveillance (15), in
persons under 18 years of age will be pro-
spectively identified through referrals to pediatric
nephrologists; these sites have fairly well-
defined population bases, so estimating the
incidence rate of pediatric HUS will be possible.
Including adult HUS may be possible in the
future. Because HUS is a distinctive and serious
illness, its diagnosis is not likely to be affected by
the first surveillance problem, the vagaries of
clinical and laboratory practices that can make
interpreting O157 isolation data difficult; ascer-
tainment will likely be fairly complete. Therefore,
unlike O157-based surveillance, HUS-based sur-
veillance will allow monitoring of trends in the
incidence of STEC infection and the examination
of the impact of prevention efforts and changing
or emerging routes of exposure. HUS cases iden-
tified through surveillance are being linked to
microbial diagnosis, by culturing patients’ stool
for O157 and, after screening stool for Shiga
toxin-producing colonies, for non-O157 STEC (in
the future sera may be tested for O157 or other
STEC infections). This linkage will address the
second surveillance problem—by differentiating
illness caused by the various STEC, linked micro-
bial diagnosis will allow detection of trends in the
incidence of non-O157 STEC as well as O157.
Because passive surveillance for HUS, which has
been conducted by many states and continues on
a national level, lacks the microbial diagnostic
component of the active surveillance system, it
cannot show these trends. Active surveillance for
HUS will be an efficient approach to STEC
surveillance because essentially all patients
with diarrhea-associated HUS have STEC
infections—HUS is a more potent indicator than
any other clinical syndrome.
This surveillance effort can provide the frame-
work for future investigations in several areas.
Clinical and immunologic risk factors for HUS
following O157 infection could be defined through
case-control studies using as controls patients
with O157 infection but without HUS. Risk
factors for infection with non-O157 STEC could
be characterized. Serum collected from patients
with non-O157 STEC infections could be used to
develop serologic tests for infection with these
organisms. Methods for Shiga toxin identification
in stool could be evaluated. Finally, HUS treat-
ments could be evaluated in a well-defined
patient population and study network.
Reliable surveillance data are critical to tar-
geting prevention efforts and defining their
success. A national HUS surveillance system
will provide the information needed to measure
the impact of new and changing vehicles of
STEC transmission, evaluate the effectiveness
of prevention measures, and detect illness
caused by non-O157 STEC.
Barbara E. Mahon,* Patricia M. Griffin,† Paul S.
Mead,† Robert V. Tauxe†
*UMDNJ-Robert Wood Johnson Medical School,
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